QNCX · As filed with the SEC
Quince Therapeutics income statement, by fiscal year
The statement as Quince Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | 35,382,000 | 18,590,000 | 9,447,000 | 25,178,000 |
| General and administrative | 15,047,000 | 17,580,000 | 17,695,000 | 26,012,000 |
| Goodwill impairment charge | — | — | — | 825,000 |
| Goodwill impairment charge | — | — | 0 | — |
| Goodwill impairment charge | 0 | 17,130,000 | — | — |
| Intangible asset impairment charge | — | 0 | 5,900 | — |
| Fair value adjustment for contingent consideration | — | 3,985 | 1,578 | — |
| Fair value adjustment for contingent consideration | 7,639,000 | — | — | — |
| Total operating expenses | 58,068,000 | 57,285,000 | 34,620,000 | 52,015,000 |
| Loss from operations | (58,068,000) | (57,285,000) | (34,620,000) | (52,015,000) |
| Fair value adjustment for long-term debt | — | (1,709) | (338) | — |
| Fair value adjustment for debt | (2,043,000) | — | — | — |
| Fair value adjustment for warrants | (21,470,000) | — | — | — |
| Warrant issuance costs | (914,000) | — | — | — |
| Interest income | 1,244,000 | 2,929,000 | 3,478,000 | 1,068,000 |
| Other income (expense), net | 486,000 | (676,000) | (102,000) | (997,000) |
| Net loss before income tax expense | (80,765,000) | (56,741,000) | (31,582,000) | (51,944,000) |
| Income tax benefit | — | — | 197,000 | — |
| Income tax expense | (3,214,000) | (87,000) | — | 284,000 |
| Net loss | (83,979,000) | (56,828,000) | (31,385,000) | (51,660,000) |
| Other comprehensive loss: | ||||
| Foreign currency translation adjustments | — | (3,160) | 2,789 | 248 |
| Foreign currency translation adjustments | 5,849,000 | — | — | — |
| Unrealized gain (loss) on available-for-sale securities | (64,000) | 78,000 | 547,000 | (458,000) |
| Total comprehensive loss | (78,194,000) | (59,910,000) | (28,049,000) | (51,870,000) |
| Net loss per share - basic (in USD per share) | (1.68) | (1.31) | (0.84) | (1.54) |
| Net loss per share - diluted (in USD per share) | (1.68) | (1.31) | (0.84) | (1.54) |
| Weighted average shares of common stock outstanding - basic (in shares) | 50,096,897 | 43,262,269 | 37,237,149 | 33,496,534 |
| Weighted average shares of common stock outstanding - diluted (in shares) | 50,096,897 | 43,262,269 | 37,237,149 | 33,496,534 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.